Endocannabinoids and liver disease† ‡
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Endogenous cannabinoids are ubiquitous lipid signaling molecules that are able to partially mimic the actions produced by Δ9-tetrahydrocannabinol, the compound responsible for most of the psychological effects of marijuana. Endocannabinoids are involved in an important number of central and peripheral physiological effects and are derived from arachidonic acid. They include anandamide (arachidonylethanolamide [AEA]), 2-arachydonyl glycerol (2-AG), N-arachydonoyldopamine, noladin ether, and virodhamine,1 the former two being the most extensively investigated. The interaction of these substances with two different types of receptors results in most of their biological effects. By coupling to Gi/o proteins the cannabinoid CB1 receptor may inhibit adenylate cyclase activity and voltage-activated Ca2+ channels or else stimulate protein kinase activity and inwardly rectify K+ channels. The cannabinoid CB2 receptor transduces similar biological responses, with the exception of those acting through voltage-activated Ca2+ and inwardly rectifying K+ channels.2, 3 Moreover, AEA also can interact with the transient receptor potential vanilloid type 1 protein (TRPV1), which is also known as the VR1 receptor and belongs to the large family of TRP ion channels.4, 5 The cannabinoid CB1 receptor is densely distributed in areas of the brain related to motor control, cognition, emotional response, motivated behavior, and homeostasis. In addition, the CB1 receptor is also peripherally located in vessels, in endothelial6 and smooth muscle cells,7, 8 and in the terminal endings of perivascular nerves, which also express TRPV1 receptors.9 By contrast, CB2 receptors are mainly restricted to immune tissues and cells. AEA, arachidonylethanolamide; HSC, hepatic activated stellate cell. In addition to displaying psychoactive, analgesic, hypothermic, antiemetic, and locomotor inhibitory properties, endocannabinoids also exhibit vasorelaxing and anti-inflammatory activities and stimulate food intake. Several investigations have also suggested that these substances may be antitumoral agents, since they induce the regression of skin tumors and gliomas, a phenomenon thought to be due to their antiproliferative and apoptotic properties.10, 11 Endogenous cannabinoids are released upon demand from lipid precursors in a receptor-dependent manner. AEA is produced from the enzymatic cleavage of N-arachydonyl phosphatidylethanolamine by a Ca2+-dependent N-acetyltransferase in several cell types, including neurons, human umbilical vein endothelial cells, neuroblastoma cells, leukocytes, monocytes, and macrophages.12 Endocannabinoids are transported into cells by a specific uptake system and degraded by two well-characterized enzymes, fatty acid amidehydrolase and monoacylglycerol lipase.13, 14 Recent pharmacological advances have led to the synthesis of cannabinoid receptor agonists and antagonists, anandamide uptake blockers, and selective inhibitors of endocannabinoid degradation. These pharmacological tools have also enabled investigation of the role of endocannabinoids in physiological and pathological conditions.15 Awareness of the pathophysiological importance of the endogenous cannabinoid system in advanced liver disease has grown during the past few years. Initially, investigations focusing on the vasorelaxing properties of endocannabinoids demonstrated that these substances are involved in the pathogenesis of the cardiovascular dysfunction occurring in advanced liver disease.16, 17 Systemic administration of a selective CB1 receptor antagonist, SR141716A, increased arterial pressure and total peripheral resistance and decreased mesenteric blood flow and portal pressure in rats with cirrhosis and ascites, but not in control rats. These effects were peripherally mediated because injection of the antagonist in the fourth cerebral ventricle of both control rats and rats with cirrhosis failed to alter blood pressure. Furthermore, a significant reduction in mean arterial pressure was observed in recipient animals in response to circulating blood cells of rats with cirrhosis, a phenomenon not observed when cells were collected from control rats. A remarkably similar pattern of cardiovascular behavior was observed in recipient animals in response to isolated circulating monocytes of rats with cirrhosis and ascites.17 This hypotensive effect induced by isolated monocytes of rats with cirrhosis was prevented by the previous administration of the CB1-specific receptor antagonist. Since it has been shown that AEA can elicit arterial hypotension through CB1 receptors, it is likely that this endocannabinoid mediates, at least in part, the hypotension induced by monocytes of rats with cirrhosis. Increased circulating levels of AEA have also been described in patients with cirrhosis.18 More recently, experiments in isolated third-order mesenteric arteries of rats with cirrhosis19 and ascites have shown that these vessels display an altered and differenti
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Cited by
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Unexpectedly, recent data also implicate endocannabinoids and their receptors in several aspects of acute and chronic liver disease, including hemodynamic changes, modulation of inflammatory processes, fibrosis, and altered brain function (reviewed in Gabbay et al., 2005; Jimenez, 2005).”
BackgroundModulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell
Juan-Picó, P., Fuentes, E., Javier Bermúdez-Silva, F., Javier Díaz-Molina, F., Ripoll, C., Rodríguez de Fonseca, F., & Nadal, A. (2006) · Cell Calcium · doi:10.1016/j.ceca.2005.10.005 · Cited by 258
The hepatic apelin system: A new therapeutic target for liver disease†
Principe, A., Melgar‐Lesmes, P., Fernández‐Varo, G., del Arbol, L. R., Ros, J., Morales‐Ruiz, M., Bernardi, M., Arroyo, V., & Jiménez, W. (2008) · Hepatology · doi:10.1002/hep.22467 · Cited by 127
Self-citationSong, B.-J., Abdelmegeed, M. A., Henderson, L. E., Yoo, S.-H., Wan, J., Purohit, V., Hardwick, J. P., & Moon, K.-H. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/781050 · Cited by 67
Metadata
- Authors
- Jiménez, W.
- Venue
- Hepatology
- Published
- 2005-05
- Volume
- 41
- Issue
- 5
- Pages
- 983-985
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1508944460
- Cited by
- 74
- References
- 2
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.